Compounds > ethyl 2,5-dihydroxycinnamate

Page last updated: 2024-12-08

ethyl 2,5-dihydroxycinnamate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID Source	ID
PubMed CID	6441630
CHEMBL ID	277077
SCHEMBL ID	3366448
MeSH ID	M0232774

Synonyms (8)

Synonym
ethyl 2,5-dihydroxycinnamate
CHEMBL277077
SCHEMBL3366448
ethyl (e)-3-(2,5-dihydroxyphenyl)prop-2-enoate
2,5-mec
2-propenoic acid, 3-(2,5-dihydroxyphenyl)-, ethyl ester
40931-15-5
AMY32478

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (18)

Assay ID	Title	Year	Journal	Article
AID200813	Inhibitory concentration required against SNB19 CNS cancer cell line	2001	Bioorganic & medicinal chemistry letters, May-07, Volume: 11, Issue:9	Syntheses of certain 3-aryl-2-propenoates and evaluation of their cytotoxicity.
AID144956	Inhibitory concentration required against NCI-H23 lung cancer cell line	2001	Bioorganic & medicinal chemistry letters, May-07, Volume: 11, Issue:9	Syntheses of certain 3-aryl-2-propenoates and evaluation of their cytotoxicity.
AID214782	Inhibitory concentration required against UACC62 melanoma cell line	2001	Bioorganic & medicinal chemistry letters, May-07, Volume: 11, Issue:9	Syntheses of certain 3-aryl-2-propenoates and evaluation of their cytotoxicity.
AID103423	Inhibitory concentration required against MCF-7 breast cancer cell line	2001	Bioorganic & medicinal chemistry letters, May-07, Volume: 11, Issue:9	Syntheses of certain 3-aryl-2-propenoates and evaluation of their cytotoxicity.
AID101007	Inhibitory concentration required against LOX-IMVI melanoma cell line	2001	Bioorganic & medicinal chemistry letters, May-07, Volume: 11, Issue:9	Syntheses of certain 3-aryl-2-propenoates and evaluation of their cytotoxicity.
AID101799	Inhibitory concentration required against MDA-MB-231 breast cancer cell line	2001	Bioorganic & medicinal chemistry letters, May-07, Volume: 11, Issue:9	Syntheses of certain 3-aryl-2-propenoates and evaluation of their cytotoxicity.
AID46278	Inhibitory concentration required against COLO 205 colon cancer cell line	2001	Bioorganic & medicinal chemistry letters, May-07, Volume: 11, Issue:9	Syntheses of certain 3-aryl-2-propenoates and evaluation of their cytotoxicity.
AID85439	Inhibitory concentration required against HT 29 colon cancer cell line	2001	Bioorganic & medicinal chemistry letters, May-07, Volume: 11, Issue:9	Syntheses of certain 3-aryl-2-propenoates and evaluation of their cytotoxicity.
AID9858	Inhibitory concentration required against ACHN renal cancer cell line	2001	Bioorganic & medicinal chemistry letters, May-07, Volume: 11, Issue:9	Syntheses of certain 3-aryl-2-propenoates and evaluation of their cytotoxicity.
AID79806	Inhibitory concentration required against HCC2998 colon cancer cell line	2001	Bioorganic & medicinal chemistry letters, May-07, Volume: 11, Issue:9	Syntheses of certain 3-aryl-2-propenoates and evaluation of their cytotoxicity.
AID202226	Inhibitory concentration required against SW620 colon cancer cell line	2001	Bioorganic & medicinal chemistry letters, May-07, Volume: 11, Issue:9	Syntheses of certain 3-aryl-2-propenoates and evaluation of their cytotoxicity.
AID8620	Inhibitory concentration required against A 431 human epidermoid carcinoma cell line	2001	Bioorganic & medicinal chemistry letters, May-07, Volume: 11, Issue:9	Syntheses of certain 3-aryl-2-propenoates and evaluation of their cytotoxicity.
AID80256	Inhibitory concentration against HCT 116 human colon cancer cell line	2001	Bioorganic & medicinal chemistry letters, May-07, Volume: 11, Issue:9	Syntheses of certain 3-aryl-2-propenoates and evaluation of their cytotoxicity.
AID80366	Inhibitory concentration required against HCT 15 colon cancer cell line	2001	Bioorganic & medicinal chemistry letters, May-07, Volume: 11, Issue:9	Syntheses of certain 3-aryl-2-propenoates and evaluation of their cytotoxicity.
AID53779	Inhibitory concentration required against DLD-1 colon cancer cell line	2001	Bioorganic & medicinal chemistry letters, May-07, Volume: 11, Issue:9	Syntheses of certain 3-aryl-2-propenoates and evaluation of their cytotoxicity.
AID156018	Inhibitory concentration required against PC-3 prostate cancer cell line	2001	Bioorganic & medicinal chemistry letters, May-07, Volume: 11, Issue:9	Syntheses of certain 3-aryl-2-propenoates and evaluation of their cytotoxicity.
AID8631	Inhibitory concentration required against A 549 lung cancer cell line	2001	Bioorganic & medicinal chemistry letters, May-07, Volume: 11, Issue:9	Syntheses of certain 3-aryl-2-propenoates and evaluation of their cytotoxicity.
AID39252	Inhibitory concentration against B16 murine melanoma cell line	2001	Bioorganic & medicinal chemistry letters, May-07, Volume: 11, Issue:9	Syntheses of certain 3-aryl-2-propenoates and evaluation of their cytotoxicity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	6 (85.71)	18.2507
2000's	1 (14.29)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (14.29%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	6 (85.71%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
tyrphostin 25 [no description available]	1.99	1	0	benzenetriol
lavendustin a lavendustin A: from Streptomyces griseolavendus; structure given in first source	2	1	0	aromatic amine
tyrosine Tyrosine: A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.. tyrosine : An alpha-amino acid that is phenylalanine bearing a hydroxy substituent at position 4 on the phenyl ring.	1.98	1	0	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; proteinogenic amino acid; tyrosine	EC 1.3.1.43 (arogenate dehydrogenase) inhibitor; fundamental metabolite; micronutrient; nutraceutical
1,4-dihydroxyanthraquinone 1,4-dihydroxyanthraquinone: structure given in first source. quinizarin : A dihydroxyanthraquinone having the two hydroxy substituents at the 1- and 4-positions; formally derived from anthraquinone by replacement of two hydrogen atoms by hydroxy groups	2	1	0	dihydroxyanthraquinone	dye
u 73122 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione: structure given in first source. U-73122 : An aza-steroid that is 3-O-methyl-17beta-estradiol in which the 17beta-hydroxy group is replaced by a 6-(maleimid-1-yl)hexylamino group. An inibitor of phospholipase C.	1.99	1	0	aromatic ether; aza-steroid; maleimides	EC 3.1.4.11 (phosphoinositide phospholipase C) inhibitor
demecolcine Demecolcine: An alkaloid isolated from Colchicum autumnale L. and used as an antineoplastic.. (-)-demecolcine : A secondary amino compound that is (S)-colchicine in which the N-acetyl group is replaced by an N-methyl group. Isolable from the autumn crocus, Colchicum autumnale, it is less toxic than colchicine and is used as an antineoplastic.	1.99	1	0	alkaloid; secondary amino compound	antineoplastic agent; microtubule-destabilising agent
wortmannin [no description available]	1.99	1	0	acetate ester; cyclic ketone; delta-lactone; organic heteropentacyclic compound	anticoronaviral agent; antineoplastic agent; autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector; Penicillium metabolite; radiosensitizing agent
methyl caffeate methyl caffeate: from plant Gaillardia pulchella. methyl caffeate : An alkyl caffeate ester formed by the formal condensation of caffeic acid with methyl alcohol.	2	1	0	alkyl caffeate ester; methyl ester
tamoxifen [no description available]	2	1	0	stilbenoid; tertiary amino compound	angiogenesis inhibitor; antineoplastic agent; bone density conservation agent; EC 1.2.3.1 (aldehyde oxidase) inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; estrogen antagonist; estrogen receptor antagonist; estrogen receptor modulator
genistein [no description available]	2	1	0	7-hydroxyisoflavones	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; geroprotector; human urinary metabolite; phytoestrogen; plant metabolite; tyrosine kinase inhibitor
ethyl caffeate (E)-ethyl 3-(3,4-dihydroxyphenyl)prop-2-enoate: structure in first source. ethyl trans-caffeate : An ethyl ester resulting from the formal condensation of the carboxy group of trans-caffeic acid with ethanol.	2	1	0	alkyl caffeate ester; ethyl ester; hydroxycinnamic acid	anti-inflammatory agent; antineoplastic agent; metabolite
erbstatin erbstatin: from actinomycetes; an inhibitor of EGF-receptor kinase & other protein-tyrosine kinases; structure in first source	3.08	1	0
methyl 2,5-dihydroxycinnamate methyl 2,5-dihydroxycinnamate: structure given in first source. 2,5-dihydroxycinnamic acid methyl ester : A cinnamate ester that is the methyl ester of 2,5-dihydroxycinnamic acid.	3.49	2	0	cinnamate ester; hydroquinones; methyl ester	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; geroprotector; human urinary metabolite; plant metabolite
propyl caffeate propyl caffeate: has antioxidant activity; structure in first source	2	1	0
ucn 1028 c calphostin C: structure given in first source; isolated from Cladosporium cladosporioides	1.99	1	0
epidermal growth factor Epidermal Growth Factor: A 6-kDa polypeptide growth factor initially discovered in mouse submaxillary glands. Human epidermal growth factor was originally isolated from urine based on its ability to inhibit gastric secretion and called urogastrone. Epidermal growth factor exerts a wide variety of biological effects including the promotion of proliferation and differentiation of mesenchymal and EPITHELIAL CELLS. It is synthesized as a transmembrane protein which can be cleaved to release a soluble active form.	1.99	1	0

Condition	Indicated	Relationship Strength	Studies	Trials
Cell Transformation, Viral An inheritable change in cells manifested by changes in cell division and growth and alterations in cell surface properties. It is induced by infection with a transforming virus.	0	2.9	1	0
Astrocytoma, Grade IV [description not available]	0	1.99	1	0
Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.	0	1.99	1	0
Breast Cancer [description not available]	0	2	1	0
Breast Neoplasms Tumors or cancer of the human BREAST.	0	2	1	0